CCL2/CCR2 signaling in cancer pathogenesis.

Hao Q, Vadgama JV, Wang P. · 2020

Read CCL2/CCR2 signaling in cancer pathogenesis. by Hao Q, Vadgama JV, Wang P. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7257158.txt.

Introduction

Hao, Vadgama and Wang review how a small immune signal helps cancers grow and spread. Their review appeared in Cell Communication and Signaling. The signal is CCL2, and its main receptor is CCR2. CCL2 draws immune cells toward tumors. High levels of both have been linked to worse disease in many cancers.

The authors focus most on prostate cancer. They explain how CCL2 and CCR2 support tumor growth, new blood vessels and spread to bone. They also cover links to relapse and to obesity. Work from their group and others is used to judge the pair as a drug target. Readers get a clear map of one pathway in cancer biology.

Catalog record

CREATORHao Q, Vadgama JV, Wang P.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE70 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7257158

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

CCL2/CCR2 signaling in cancer pathogenesis By Qiongyu Hao, Jaydutt V Vadgama, Piwen Wang Published in: Cell Communication and Signaling : CCS DOI: 10.1186/s12964-020-00589-8 ABSTRACT Abstract Chemokines are a family of small cytokines, which guide a variety of immune/inflammatory cells to the site of tumor in tumorigenesis. A dysregulated expression of chemokines is implicated in different types of cancer including prostate cancer. The progression and metastasis of prostate cancer involve a complex network of chemokines that regulate the recruitment and trafficking of immune cells. The chemokine CCL2 and its main receptor CCR2 have been receiving particular interest on their roles in cancer pathogenesis. The up-regulation of CCL2/CCR2 and varied immune conditions in prostate cancer, are associated with cancer advancement, metastasis, and relapse. Here we reviewed recent findings, which link CCL2/CCR2 to the inflammation and cancer pathogenesis, and discussed the therapeutic potential of CCL2/CCR2 axis in cancer treatment based on results from our group and other investigators, with a major focus on prostate cancer. [Figure: Video Abstract] BACKGROUND Chemokines and cytokines are core regulators in cancer microenvironment which has been established as one of the hallmark drivers of cancer [1]. The cellular composition of tumor microenvironment is frequently modulated by cytokine milieu secreted by cancer cells in favor of tumor progression [1, 2]. Inflammation is one of the initiating processes of carcinogenesis where inflammatory/immune cells are trafficked into the tumor microenvironment by specific cytokines termed chemokines [3]. Chemokines are a family of small cytokines with ability to induce chemotaxis, a process where directed migration of cells expressing the appropriate chemokine receptor occurs towards higher local concentrations of chemokine ligands. Chemokines guide a variety of immune cells to the site of tumor initiation and subsequently lead to an inflammatory/immune response [3]. Chemokines contribute to the development of malignancy through roles in progression, migration, angiogenesis, and metastases in multiple cancer types [4]. Elevated levels of cytokines/chemokines such as IL-8 (interleukin-8), CXCL1 (Chemokine (C-X-C motif) Ligand 1), CCL2 (Chemokine (C-C motif) ligand 2, also known as monocyte chemoattractant protein-1, MCP-1), and CXCL5 have been associated with increased growth and progression of breast, ovarian, and prostate cancer [5–9]. In addition to tumor cells, various cells in the host microenvironment, including infiltrating leukocytes, endothelial cells, and fibroblasts, as well as adipocytes, are able to produce cytokines/chemokines such as CCL2 for tumor growth and progression [4, 10–26]. The upregulation of CCR2 has been found to be associated with advanced cancer, metastasis, and relapse [27]. The overexpression of CCL2 and resultant promotion of tumor growth have also been observed in breast [11, 12], ovarian [13], esophageal [14], gastric [15], renal cell [16], lung [17], colon [18], and papillary thyroid cancers [19]. In breast tumors, CCL2 overexpression was associated with advanced disease, tumor progression, and angiogenesis [20], and predicts prognosis and recurrence [22]. In breast tumor bone metastases, CCL2 overexpression led to enhanced osteolysis and the release of bone matrix-bound angiogenic factors, including platelet-derived growth factor, fibroblast growth factors-1, and transforming growth factor b [21]. Several studies have also demonstrated that serum CCL2 was elevated and associated with tumor stage in patients with breast, ovarian, and lung cancers [23–25]. Prostate cancer (PCa) is one of the most common types of cancer and the second leading cause of cancer death in men in the United States [28]. The morbidity of PCa has still been increasing among elderly men over the last decade [29]. PCa progression and metastasis is driven by many factors including the abnormalities of many growth factors and cytokines, among others such as the mutation and/or amplification of androgen receptor and other oncogenes and the inhibition of tumor suppressor genes [30–32]. The overexpression of CCL2 and its main receptor CCR2 (CC chemokine receptor 2) has been observed in both primary and metastatic PCa cells [33]. In addition, Lu et al. reported that elevated serum CCL2 was associated with bone metastasis in a study of 39 prostate cancer patients at various stages, suggesting the possibility of using serum CCL2 as a prognostic biomarker [26]. Since elevated CCL2 in circulation is also one of the typical features of obesity [34–38], this supports the role of CCL2 in connection of obesity and cancer promotion. These results suggest the critical role of the CCL2-CCR2 axis in cancer progression and its potential use as therapeutic target. Classification of chemokines Chemokines are a family of small chemotactic cytokines, which are signaling proteins secreted by cells. Chemokines have been classified based on the relative position of cysteine residues near the N terminus into four major families: CC, CXC, C, and CX3C. The CC chemokine (or β-chemokine) proteins have two adjacent cysteines near their amino terminus. There have been at least 27 distinct members of this subgroup reported for mammals, called CC chemokine ligands (CCL)-1 to − 28. CXC chemokines (or α-chemokines) have two N-terminal cysteines, which are separated by one amino acid, represented in this name with an “X”. There have been 17 different CXC chemokines described in mammals. C chemokines (or γ chemokines), are unlike other chemokines in that they have only two cysteines, one N-terminal cysteine and one cysteine downstream. Two chemokines have been described for this subgroup and are called XCL1 (lymphotactin-α) and XCL2 (lymphotactin-β). CX3C chemokines (or d-chemokines) have three amino acids between the two cysteines. The only CX3C chemokine discovered to date is called fractalkine (or CX3CL1). Chemokine receptors are G-protein coupled receptors located in the cell membrane, and they transduce the extracellular signal by interacting with chemokine ligands [39]. Chemokines have substantial effects as chemotactic factors on normal development, inflammation, atherosclerosis, and angiogenesis [40]. Chemokines have been implicated in many aspects of tumorigenesis, including the regulation of cancer cell growth, angiogenesis, metastasis, and host immune response [41]. CCL2/CCR2 CCL2 (MCP-1) is a member of the CC chemokine family [42]. The CCL2 gene is located in the q11.2-q12 region of human chromosome 17, and it encodes a precursor protein of 99 amino acids that matures into 75 amino acids in size [43]. CCL2 is initially described as a “tumor-derived chemotactic factor”, and has been shown to be a potent chemoattractant for several types of immune cells, including the monocytes, natural killer cells, memory T cells, and immature dendritic cells, thereby mediating multiple proinflammatory effects and neoangiogenesis [44–50]. CCR2 has been found to be expressed by multiple cell types including monocytes, dendritic cells (DCs), endothelial cells, and cancer cells [51–54]. CCL2 functions through binding to CCR2, one of 19 members of the human chemokine receptor family [55]. In addition to CCL2, CCR2 has several other high-affinity ligands, including CCL7 (MCP-2), CCL8 (MCP-3), CCL13 (MCP-4), and CCL12 (MCP-5) - a murine chemokine with close homology to human CCL2 [56–59], with an order of strength in binding to CCR2 as CCL2 > > CCL13 = CCL8 > CCL7 [60]. Monocytes, immature dendritic cells, and T-cell subpopulations have high expression of CCR2 which mediates their migration towards CC chemokines such as CCL2 [61]. CCL2-CCR2 signaling axis is implicated in many inflammatory and neurodegenerative diseases such as atherosclerosis, multiple sclerosis, asthma, neuropathic pain, diabetic nephropathy, and cancer [62, 63], and therefore is explored as a potential target for the treatment of these diseases. THE ROLE OF CCL2-CCR2 AXIS INVOLVING IMMUNE CELLS IN TUMOR PROGRESSION The inflammatory

Read the complete text